Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy

Eric R Lutz, Heather Kinkead, Elizabeth M. Jaffee, Lei Zheng

Research output: Contribution to journalArticlepeer-review


Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.

Original languageEnglish (US)
Pages (from-to)e962401-1-e962401-3
Issue number11
StatePublished - Nov 2 2014


  • pancreatic cancer
  • tumor immunotherapy
  • tumor vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy'. Together they form a unique fingerprint.

Cite this